🇺🇸 FDA
Pipeline program

BCT197

MBCT206

Phase 2 small_molecule completed

Quick answer

BCT197 for Pulmonary Disease, Chronic Obstructive is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Pulmonary Disease, Chronic Obstructive
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials